Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18759969 | 0.95 | SMN1; SMN2 (0.57) | SMN1; SMN2KMT2ANPC1POLBMEN1 | |
| SCHEMBL7619697 | 0.90 | SMN1; SMN2 (0.70) | SMN1; SMN2KMT2ANPC1POLBMEN1 | |
| SCHEMBL18759961 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL18759956 | 0.81 | CYP3A4 (0.47) | SMN1; SMN2KMT2AMEN1HTTGAA | |
| SCHEMBL18759883 | 0.81 | DPP4 (0.45) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL6422682 | 0.80 | MAOA (0.52) | SMN1; SMN2KMT2ANPC1POLBMEN1 | |
| SCHEMBL6424005 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2ANPC1POLBMEN1 | |
| SCHEMBL4183874 | 0.80 | NR1H2 (0.60) | SMN1; SMN2NPC1POLBRAB9A | |
| SCHEMBL30471770 | 0.79 | GHSR (0.54) | SMN1; SMN2KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL26877961 | 0.79 | GHSR (0.54) | SMN1; SMN2KMT2AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053458-B2 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-08-21 | — | — | US | disclosed |
| US-20170145007-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2017-05-25 | — | — | US | disclosed |
| EP-3159338-A2 | PYRIMIDINE-2,4-DIAMINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2017-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145007-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT | ALK, NPM1, ETV6 | SMN1; SMN2 2442/4885KMT2A 536/4885NPC1 422/4885 |
| US-10053458-B2 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient | ALK, NPM1, ETV6 | SMN1; SMN2 2442/4885KMT2A 536/4885NPC1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.